Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex

Figure 2

Molecular structure of sirolimus and its analogues. They all share a central macrolide chemical structure and have a unique R group at the C40 position.